GLP-1 medications have significantly changed the treatment landscape for obesity. Medications such as semaglutide and tirzepatide have introduced new possibilities for patients seeking medical weight management, offering meaningful weight loss without surgery.
However, not everyone responds to these medications in the same way. Some patients experience adverse effects that make continued treatment difficult, while others achieve less weight loss than expected despite medication therapy.
A newly published study from Cleveland Clinic, appearing in Annals of Surgery in 2026, provides important insight into what may come next for these patients: bariatric surgery.
The findings suggest that patients who discontinued semaglutide or tirzepatide because of intolerable side effects, or who experienced inadequate weight loss while taking these medications, achieved substantial weight loss two years after undergoing bariatric surgery.
This research adds to the growing understanding that obesity treatment is not limited to one approach. It also reinforces the continuing role of metabolic and bariatric surgery in an era increasingly shaped by medical weight-loss therapies.
What Did the Cleveland Clinic Study Find?
The study, titled Bariatric Surgery as a Rescue Strategy After Semaglutide or Tirzepatide, evaluated weight-loss outcomes among adults who underwent either Roux-en-Y gastric bypass or sleeve gastrectomy after experiencing difficulties with GLP-1 medications.
Researchers analyzed data from 4,929 patients who underwent bariatric surgery at Cleveland Clinic hospitals between 2018 and 2024.
Among these patients:
- 4,661 had no previous exposure to semaglutide or tirzepatide.
- 61 had discontinued one of these medications because of intolerable adverse effects.
- 207 had experienced inadequate weight loss while taking the medications.
The researchers then evaluated total body weight loss two years after surgery, comparing outcomes according to the type of procedure and whether patients had type 2 diabetes.
The results were particularly notable for patients who had previously struggled with medication-based weight management.
How Much Weight Did Patients Lose After Surgery?
Patients who had discontinued GLP-1 medications due to adverse effects or inadequate results achieved clinically meaningful weight loss following bariatric surgery.
The following table summarizes the estimated total body weight loss at two years, as reported in the study.
Estimated Total Body Weight Loss Two Years After Surgery
| Patient group | Gastric bypass (no T2DM) | Gastric bypass (T2DM) | Gastric sleeve (no T2DM) | Gastric sleeve (T2DM) |
| Medication intolerance | 27.9% | 22.7% | 20.1% | 21.6% |
| Inadequate medication response | 35.8% | 27.4% | 14.3% | 14.2% |
| No prior medication exposure | 33.3% | 28.7% | 23.6% | 19.9% |
T2DM = Type 2 Diabetes Mellitus. Figures represent estimated total body weight loss, not excess weight loss.
One of the most interesting findings involved patients who had experienced inadequate weight loss with semaglutide or tirzepatide.
In this group, adjusted analysis showed that patients who underwent Roux-en-Y gastric bypass achieved an average of 32.7% total body weight loss at two years, compared with 17.8% among those who underwent sleeve gastrectomy.
This represented a difference of 14.9 percentage points.
These findings suggest that the type of bariatric procedure may be an important consideration for patients who have not achieved sufficient results with GLP-1 medications. However, procedure selection must always account for individual medical history, metabolic conditions, anatomy, and other clinical factors.
What Does This Mean for Patients Who Have Not Succeeded With GLP-1 Medications?
For patients who have invested time in medical weight management without achieving their desired results, these findings offer an important perspective.
There are several reasons why GLP-1 treatment may not be successful for everyone:
- Medication intolerance: Gastrointestinal and other adverse effects may make continued treatment difficult or unsustainable.
- Inadequate response: Some patients experience limited weight loss despite taking the medication.
- Treatment limitations: Long-term medication management may present challenges related to tolerability, access, cost, or the need for continued treatment.
The Cleveland Clinic study suggests that experiencing these difficulties does not mean that meaningful weight loss is out of reach.
Bariatric surgery offers a different therapeutic approach, producing changes in stomach capacity, appetite regulation, hormonal signaling, and metabolic function. Depending on the procedure, these mechanisms can contribute to substantial and sustained weight loss.
The Evolving Relationship Between Medication and Bariatric Surgery
The emergence of GLP-1 medications has changed how obesity is treated, but it has not eliminated the role of bariatric surgery.
Instead, it has expanded the conversation about how different treatment approaches can serve patients at different stages of their weight-management journey.
Historically, bariatric surgery was often considered after patients had attempted diet, exercise, and other non-surgical interventions without achieving sufficient results.
Today, the treatment landscape is broader.
Some patients may benefit from lifestyle interventions and medical management. Others may achieve meaningful results with GLP-1 medications. For patients who do not respond adequately, cannot tolerate treatment, or require a different therapeutic approach, metabolic and bariatric surgery remains an established option.
These treatments should not necessarily be viewed as competing alternatives. They are different tools within the broader medical management of obesity.
The most appropriate treatment depends on the patient’s health history, weight-loss goals, metabolic conditions, previous treatments, and overall medical evaluation.
Choosing Between Gastric Sleeve and Gastric Bypass
The Cleveland Clinic findings also raise an important question: Does the type of bariatric surgery matter for patients who have experienced inadequate results with GLP-1 medications?
In this particular study, Roux-en-Y gastric bypass was associated with greater two-year weight loss than sleeve gastrectomy among patients with an inadequate response to semaglutide or tirzepatide.
However, this does not mean gastric bypass is automatically the best option for every patient.
Both procedures have established roles in obesity treatment, but they differ in their surgical techniques, metabolic effects, potential complications, and long-term considerations.
Gastric Sleeve (Sleeve Gastrectomy)
This procedure involves removing approximately 75–80% of the stomach, creating a smaller, sleeve-shaped stomach. It reduces stomach capacity and influences appetite-related hormones.
Gastric Bypass (Roux-en-Y Gastric Bypass)
This procedure creates a smaller stomach pouch and reroutes a portion of the small intestine. In addition to restricting food intake, it produces significant changes in digestive and metabolic signaling.
The decision between these procedures should be individualized. Factors such as gastroesophageal reflux, type 2 diabetes, previous surgical history, BMI, and other medical considerations may influence which procedure is more appropriate.
An Important Perspective: Obesity Requires Individualized Treatment
Perhaps the most important takeaway from this research is that obesity is a complex, chronic disease, and its treatment should not be limited to a single method.
Not every patient responds to medication in the same way. Not every patient is a candidate for the same surgical procedure. And not every successful treatment journey follows the same path.
The development of GLP-1 medications has created additional opportunities for patients, while research such as this Cleveland Clinic study demonstrates that bariatric surgery continues to offer meaningful results for individuals who have not achieved adequate outcomes with medication.
For patients considering their next step, a comprehensive medical evaluation can help determine which treatment approach may be most appropriate.
At Do It Bariatrics, the evaluation process with Dr. Louisiana Valenzuela is centered on understanding each patient’s medical history, previous weight-loss treatments, and individual health considerations before discussing surgical options.
The goal is not simply to find another way to lose weight. It is to identify an appropriate, medically sound approach to treating obesity and improving long-term health.
Frequently Asked Questions
- Can I have bariatric surgery if semaglutide or tirzepatide did not work for me?
Yes. Patients who have experienced inadequate weight loss or intolerable adverse effects with these medications may still be candidates for bariatric surgery. Eligibility depends on individual medical history and a comprehensive surgical evaluation.
- Does gastric bypass produce more weight loss than gastric sleeve after GLP-1 treatment?
In the Cleveland Clinic study, adjusted analysis found greater two-year total body weight loss with Roux-en-Y gastric bypass than with sleeve gastrectomy among patients who had experienced inadequate weight loss with semaglutide or tirzepatide. However, individual outcomes vary, and this finding does not establish that bypass is the right procedure for everyone.
- Do I need to try GLP-1 medications before considering bariatric surgery?
No. GLP-1 medications are not a universal prerequisite for bariatric surgery. Treatment eligibility should be evaluated according to established clinical criteria and individual circumstances.
- Does this mean bariatric surgery is replacing GLP-1 medications?
No. Both approaches have important roles in obesity treatment. They may be appropriate for different patients and at different stages of treatment. The objective is to identify the most suitable approach for each individual.
- Does bariatric surgery guarantee long-term weight loss?
No treatment guarantees a specific outcome. Bariatric surgery can produce substantial and sustained weight loss, but long-term results depend on multiple factors, including metabolic response, nutritional habits, physical activity, follow-up care, and individual health circumstances.
Reference
Aminian, A., Hammad, A. F., Sadeghmousavi, S., Daftari, G., Ferguson, L., Tu, C., Gasoyan, H., & Nissen, S. E. (2026). Bariatric Surgery as a Rescue Strategy After Semaglutide or Tirzepatide. Annals of Surgery. Advance online publication. https://doi.org/10.1097/SLA.0000000000007251
